WDR5-0103 hydrochloride

CAS No. ——

WDR5-0103 hydrochloride( WD-Repeat Protein 5-0103 )

Catalog No. M19925 CAS No. ——

WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 Get Quote
5MG 76 Get Quote
10MG 132 Get Quote
25MG 239 Get Quote
50MG 414 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    WDR5-0103 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).
  • Description
    WDR5-0103 is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd: 450 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WD-Repeat Protein 5-0103
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    WDR5
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    419.9
  • Molecular Formula
    C21H26ClN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 45 mg/mL;Ethanol: 18 mg/mL;Water: Insoluble
  • SMILES
    Cl.COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Senisterra G et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem J. 2013 Jan 1;449(1):151-159.
molnova catalog
related products
  • AG-490

    AG-490 (Tyrphostin AG 490) is a multi-targeted tyrphostin family of tyrosine kinase inhibitor.

  • CYT387

    A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM.

  • PF-06651600

    PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical